Overview

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Status:
Withdrawn
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Database analysis: - To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA) - To describe joint population of Orencia - To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria - To describe therapeutic strategies and use of health services
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept